LBT Innovations makes its first instrument sale in the EU

Medical technology and equipment developer LBT Innovations (ASX: LBT) has made its first European sale of its APAS Independence laboratory instrument (pictured).

The sale was made to one of the largest clinical laboratories in the EU, Labor Dr Wisplinghoff, which employes more than 40 medical specialists.

Laboratory director Professor Hilmar Wilplinghoff joined LBT Innovations CEO Brent Barnes in discussing the APAS machine yesterday at investor sessions in Melbourne and Adelaide.

APAS is an artificial intelligence (AI) based digital technology for automated imaging of medical culture plates used to diagnose infection.

And the APAS Independence is an imaging, interpretation, sorting and reporting machine that automatically examines culture plates for the presence of bacterial colonies.

The sale followed CE certification, reported in @AuManufacturing, and full integration of the machine into the laboratory’s workflow.

Barnes said: “This purchase reflects the positive performance experienced by the laboratory over the last 18 months.

“We are particularly pleased at the benefit this commercial sale to marquee customer in the EU brings, given their reputation for early adoption of leading edge technology.”

Picture: LBT Innovations

Subscribe to our free @AuManufacturing newsletter here.

Share this Story

Stay Informed

Go to Top